Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

References

• Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of Type 2 diabetes? Diabetes Metab.33(1), 3–12 (2007).
   Google Scholar
• Giorgino F, Laviola L, Leonardini A. Pathophysiology of Type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes. Res. Clin. Pract.68S1, S22–S29 (2005).
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab.33, 231–244 (2007).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care31(12), 1–11 (2008).
   Web of Science ®Google Scholar
• American Diabetes Association: Standards of medical care in diabetes – 2008 (position statement). Diabetes Care31(Suppl. 1), S12–S54 (2008).
   PubMed Web of Science ®Google Scholar
• Haberman AB. Addressing unmet Type 2 diabetes needs. Gen. Engineering Biotechnol. News28(1), 34–35 (2008).
   Google Scholar
• Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for Type 2 diabetes mellitus. Pharmacotherapy25(6), 810–816 (2005).
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet373, 473–481 (2008).
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Bore D, Patterson R, Noei R, Braun D, Seeger J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug inhibitors: a retrospective, cohort study. Presented at: American Diabetes Association 69th Scientific Sessions. New Orleans, LA, USA, 5–9 June 2009. Diabetes58(Suppl. 1), (2009) (Abstract 158-OR).
   Google Scholar
• Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of Type 2 diabetes. Curr. Opin. Investig. Drugs9(4), 402–413 (2008).
   PubMed Web of Science ®Google Scholar
• Vollmer K, Holst JJ, Baller B et al. Predicators of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes57, 678–687 (2008).
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple dose study in adult patients with Type 2 diabetes. Clin. Ther.30(3), 499–512
   Google Scholar
• Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther.30(3), 513–527 (2008).
   PubMed Web of Science ®Google Scholar
• Karim A, Bridson WE, Fleck P, Schuster S, Zhang W, Mekki Q. Disposition of the dipeptidyl peptidase-4 inhibitor [14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects. AAPS J.9(Suppl. 2), (2007).
   Google Scholar
• Karim A, Fleck P, Harris S, Schuster J, Zhang W, Mekki Q. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects. Presented at: 36th Meeting of the American College of Clinical Pharmacology. San Francisco, CA, USA, 9–11 September 2007. J. Clin. Pharmacol.47(9), 1207, (2007) (Abstract 105).
   Google Scholar
• Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, for the Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract.36(1), 46–55 (2009).
   Google Scholar
• Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with Type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6 June–10 June 2008. Diabetes57(Suppl. 1), (2008) (Abstract 478-P).
   Google Scholar
• Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes. Obes. Metab.11, 167–176 (2009).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic control. Diabetes Care31(12), 2315–2317 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rendell M, Gross JL, Fleck P, Wilson C, Mekki Q. Alogliptin added to insulin therapy in patients with Type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6–10 June 2008. Diabetes57(Suppl. 1), (2008) (Abstract 444-P).
   Google Scholar
• Feng J, Zhang Z, Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem.50, 2297–2300 (2007).
   PubMed Web of Science ®Google Scholar
• Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher R. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol.589, 306–314 (2008).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase-IV in the treatment of Type 2 diabetes mellitus. Curr. Opin. Pharmacol.4, 589–596 (2004).
   PubMed Web of Science ®Google Scholar
• Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents b cell glucolipotoxicity. Diabetologia47, 806–815 (2004).
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia47(3), 357–366 (2004).
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6–10 June 2008. Diabetes57(Suppl. 1), (2008) (Abstract 538–P).
   Google Scholar
• Karim A, Fleck P, Harrell RE Jr et al. Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor, in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2–5 April 2008. Clin. Pharmacol. Ther.83(Suppl. 1), S13 (2008) (Abstract PI-14).
   Google Scholar
• Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications (Third Edition). Williams & Wilkins, Baltimore, MD, USA (1995).
   Google Scholar
• Hirayama M, Matsuno K, Fujita T et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6–10 June 2008. Diabetes57(Suppl. 1), (2008) (Abstract 521-P).
   Google Scholar
• Karim A, Kissling J, Munsaka M. Effect of food on absorption and pharmacokinetics of antidiabetic drug, alogliptin, in healthy subjects. Presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. Atlanta, GA, USA, 17–19 November 2008. AAPS J.10(Suppl. 2), (2008) (Abstract 1761).
   Google Scholar
• Karim A, Fleck P, Joseph M et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007. Diabetes56(Suppl. 1), (2007) (Abstract 2117-PO).
   Google Scholar
• Fleck P, Karim A, Harris S et al. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007. Diabetes56(Suppl. 1), (2007) (Abstract 2135-PO).
   Google Scholar
• Covington P, Christopher R, Davenport M et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22–26 June 2007. Diabetes56(Suppl. 1), (2007) (Abstract 2136-PO).
   Google Scholar
• Karim A, Copa A, Fleck P, Helland J, Munsaka M, Mekki Q. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (Ortho-Novum® 1/35) in healthy adult female subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2–5 April 2008. Clin. Pharmacol. Ther.83(Suppl. 1), S14, (2008) (Abstract PI-16).
   PubMed Web of Science ®Google Scholar
• Karim A, Chiselko P, Fleck P, Harris S, Munsaka M, Mekki Q. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2–5 April 2008. Clin. Pharmacol. Ther.83(Suppl. 1), S13, (2008) (Abstract PI-15).
   Google Scholar
• Karim A, Fleck P, Harris S, Weiss M, Zhang W, Mekki Q. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2–5 April 2008. Clin. Pharmacol. Ther.83(Suppl. 1), S12 (2008) (Abstract PI-13).
   Google Scholar
• Karim A, Harris S, Fleck P, Moore R, Zhang W, Mekki Q. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state. Presented at: 36th Meeting of the American College of Clinical Pharmacology. San Francisco, CA, USA, 9–11 September 2007. J. Clin. Pharmacol.47(9), 1207 (2007) (Abstract 106).
   Google Scholar
• Karim A, Fleck P, Harris S, Munsaka M, Weiss M, Mekki Q. Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2–5 April 2008. Clin. Pharmacol. Ther.83(Suppl. 1), S14 (2008) (Abstract PI-17).
   PubMed Web of Science ®Google Scholar
• Fleck P, Christopher R, Covington P, Wilson C, Mekki Q. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with Type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6–10 June 2008. Diabetes57(Suppl. 1), (2008) (Abstract 479-P).
   Google Scholar